TP53 genetic alterations in Arab breast cancer patients: Novel mutations, pattern and distribution

Oncology Letters

Volumn 2, Issue 2, 2011, Pages 363-369

  Al Qasem, Abeer J ^a   Toulimat, Mohamed ^b   Eldali, Abdelmoneim M ^c   Tulbah, Asma ^b   Al Yousef, Nujoud ^a   Al Daihan, Sooad K ^d   Al Tassan, Nada ^e   Al Tweigeri, Taher ^f   Aboussekhra, Abdelilah ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Departments of Pathology   (Saudi Arabia)

^c Biological and Medical Research Department   (Saudi Arabia)

^d Departments of Genetics   (Saudi Arabia)

^e King Faisal Specialist Center and Research Center   (Saudi Arabia)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Breast cancer risk; Early onset; Mutations; TP53

Indexed keywords

CARCINOGEN; NITROSO DERIVATIVE; PROTEIN P53;

ARAB; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CPG ISLAND; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONSET AGE; POINT MUTATION; SAUDI ARABIA; TP53 GENE; TUMOR SUPPRESSOR GENE;

EID: 79551647685     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.236     Document Type: Article

References (39)

1. Parkin DM: International variation. Oncogene 23: 6329-6340, 2004.
2. Garfinkel L, Boring CC and Heath CW: Changing trends. An overview of breast cancer incidence and mortality Cancer 74: 222-227, 1994.
3. Polyak K, Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR and Riggins G: On the birth of breast cancer. Biochim Biophys Acta 1552: 1-13, 2001.
4. Ezzat AA, Ibrahim EM, Raja MA, Al-Sobhi S, Rostom A, Stuart RK, al-Mulhim FA, al-Amri A, al-Muhanna FA and Ajarim D: Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Breast cancer in the eastern province of Saudi Arabia. Med Oncol 16: 95-103, 1999.
5. Neuhausen SL: Ethnic differences in cancer risk resulting from genetic variation. Cancer 86: 2575-2582, 1999.
6. Perera NM and Gui GP: Multi-ethnic differences in breast cancer: current concepts and future directions. Int J Cancer 106: 463-467, 2003.
7. Polyak K: Molecular alterations in ductal carcinoma in situ of the breast. Curr Opin Oncol 14: 92-96, 2002.
8. Greenblatt MS, Bennett wP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
9. Bargonetti J and Manfredi JJ: Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14: 86-91, 2002.
10. Soussi T, Legros Y, Lubin R, Ory K and Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 57: 1-9, 1994.
11. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P and Borresen-Dale AL: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167, 2006.
12. Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries EM, Kovach JS and Sommer SS: p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 10: 681-688, 1995.
13. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen- Logmans SC, van Staveren IL, van Putten wL, Inganas M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B and Klijn JG: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60: 2155-2162, 2000.
14. Olivier M and Hainaut P: TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol 11: 353-360, 2001.
15. Lowe Sw, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
16. Borresen-Dale AL: TP53 and breast cancer. Hum Mutat 21: 292-300, 2003.
17. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G and Lonning PE: TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9: 5582-5588, 2003.
18. Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL and Jeffrey SS: TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9: R30, 2007.
19. Hartmann A, Blaszyk H, Kovach JS and Sommer SS: The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 13: 27-33, 1997.
20. Pharoah PD, Day NE and Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80: 1968-1973, 1999.
21. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614, 2002.
22. Eachkoti R, Hussain I, Afroze D, Aejazaziz S, Jan M, Shah ZA, Das BC and Siddiqi MA: BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. Cancer Lett 248: 308-320, 2007.
23. Hill KA and Sommer SS: p53 as a mutagen test in breast cancer. Environ Mol Mutagen 39: 216-227, 2002.
24. Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS and Das BC: Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treat 88: 177-186, 2004.
25. Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, De Rocquancourt A, Giacchetti S, Marty M and Calvo F: p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 69: 1145-1150, 1994.
26. Tsuda H, Iwaya K, Fukutomi T and Hirohashi S: p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 84: 394-401, 1993.
27. Saitoh S, Cunningham J, De Vries EM, et al: p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9: 2869-2875, 1994.
28. Nagai MA, Schaer Barbosa H, Zago MA, Araujo Silva w Jr, Nishimoto IN, Salaorni S, Guerreiro Costa LN, Silva Araujo M, Caldas Oliveira AG, Mourao Neto M and Brentani MM: TP53 mutations in primary breast carcinomas from white and African- Brazilian patients. Int J Oncol 23: 189-196, 2003.
29. Kouidou S, Agidou T, Kyrkou A, Andreou A, Katopodi T, Georgiou E, Krikelis D, Dimitriadou A, Spanos P, Tsilikas C, Destouni H and Tzimagiorgis G: Non-CpG cytosine methylation of p53 exon 5 in non-small cell lung carcinoma. Lung Cancer 50: 299-307, 2005.
30. Reh BD, DeBord DG, Butler MA, Reid TM, Mueller C and Fajen JM: O(6)-methylguanine DNA adducts associated with occupational nitrosamine exposure. Carcinogenesis 21: 29-33, 2000.
31. Goldman R and Shields PG: Food mutagens. J Nutr 133 (Suppl 3): 965S-973S, 2003.
32. Schroeder JC, Conway K, Li Y, Mistry K, Bell DA and Taylor JA: p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Res 63: 7530-7538, 2003.
33. Hecht SS and Hoffmann D: N-nitroso compounds and man: sources of exposure, endogenous formation and occurrence in body fluids. Eur J Cancer Prev 7: 165-166, 1998.
34. Zaidi SN, Laidlaw I, Howell A, Potten CS, Cooper DP and O'Connor PJ: Normal human breast xenografts activate N-nitrosodimethylamine: identification of potential target cells for an environmental nitrosamine. Br J Cancer 66: 79-83, 1992.
35. Scharer OD: Chemistry and biology of DNA repair. Angew Chem Int Ed Engl 42: 2946-2974, 2003.
36. 6-methylguanine acceptor protein in extracts of human breast tumor tissues. Cancer Biochem Biophys 12: 53-58, 1991.
37. Lozano JC, Nakazawa H, Cros MP, Cabral R and Yamasaki H: G-->A mutations in p53 and Ha-ras genes in esophageal papil- lomas induced by N-nitrosomethylbenzylamine in two strains of rats. Mol Carcinog 9: 33-39, 1994.
38. Mir MM, Dar NA, Gochhait S, Zargar SA, Ahangar AG and Bamezai RN: p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int J Cancer 116: 62-68, 2005.
39. Siddiqi M, Kumar R, Fazili Z, Spiegelhalder B and Preussmann R: Increased exposure to dietary amines and nitrate in a population at high risk of oesophageal and gastric cancer in Kashmir (India). Carcinogenesis 13: 1331-1335, 1992.